Study ID | Intervention sample size; control sample size | Outcome of interest | Odds ratio (95% CI) |
---|---|---|---|
Linder et al. 2010 [38] | I: 258 clinicians; C: 315 clinicians | (1) Antibiotic prescribing rate for acute respiratory infection | 0.97 (0.92–1.03) |
Peiris et al. 2015 [41] | I: 19385 patients; C: 19340 patients | (1) Patients who received appropriate screening of cardiovascular risk factors by the end of study | 1.47 (1.41–1.53) |
I: 5335 patients; C: 4846 patients | (2) Prescription rate of recommended medications for high-risk cohort | 1.25 (1.16–1.35) | |
Thomas et al. 2007 [39] | I: 252 patients; C: 231 patients | (1) Diabetes care metrics for all participating residents’ patients at study inception and completion including haemoglobin monitoring in the prior 6 months | 1.72 (1.20–2.47) |
(2) Diabetes care metrics for all participating residents’ patients at study inception and completion lipid monitoring in the prior 12 months | 1.75(1.18–2.59) | ||
Carlhed et al. 2006 [34] | I: 3786 patients; C: 2940 patients | (1) Lipid-lowering therapy at discharge | 3.26 (2.49–4.27) |
(2) Angiotensin-converting enzyme (ACE) inhibitors at discharge | 10.08 (7.31–13.90) | ||
(3) Clopidogrel at discharge | 1.96 (1.77–2.18) | ||
(4) Heparin or low-molecular weight heparin (LMWH) during hospitalisation | 3.47 (2.89–4.16) | ||
(5) Performed coronary angiography (or, for hospitals lacking in-house coronary angiography, referral to another hospital) | 3.05 (2.57–3.63) | ||
Guldberg et al. 2011 [36] | I: 1196 patients; C: 1050 patients | (1) Haemoglobin measurement sustained | 0.86 (0.59–1.25) |
I: 121 patients; C: 91 patients | (2) Haemoglobin measurement initiated if no measurement at baseline | 0.77 (0.45–1.33) | |
I: 1109 patients; C: 887 patients | (3) Cholesterol measurement sustained | 1.74 (1.35–2.24) | |
I: 208 patients; C: 258 patients | (4) Cholesterol measurement initiated if no measurement at baseline | 2.07 (1.38–3.12) | |
Carney et al. 2011 [33] | I: 23 radiologists: C: 9 radiologists | (1) Mean recall rates at time T1(0–9 months) | 1.12 (1.00–1.27) |
(2) Mean recall rates at time T2(9–18 months) | 1.10 (0.96–1.25) | ||
Gude et al. 2016 [35] | I: 7341 patients; C: 4591 patients | (1) Complete data on psychological functioning | 1.07 (0.46–2.5) |
I: 7341 patients; C: 4591 patients | (2) Complete data on social functioning | 7.95 (0.54–116.3) | |
I: 7341 patients; C: 4591 patients | (3) Complete data on lifestyle factors | 1.11 (0.45–2.75) | |
I: 4934 patients; C: 4071 patients | (4) Disease specific education completeda | 0.57 (0.31–1.06) | |
I: 5580 patients; C: 4591 patients | (5) Lifestyle modification programme completeda | 1 (0.48–2.04) | |
I: 4591 patients; C: 7341 patients | (6) Improved quality of live after CR | 0.99 (0.84–1.19) | |
I: 7341 patients; C: 4591 patients | (7) Successful smoking cessation | 1.02 (0.86–1.2) | |
I: 7341 patients; C: 4591 patients | (8) Patients receive a discharge letter with remaining lifestyle goals | 0.87 (0.27–2.81) | |
I: 4591 patients; C: 7341 patients | (9) Complete data on physical functioning | 1.32 (0.45–3.84) | |
I: 4591 patients; C: 7341 patients | (10) Complete data concerning cardiovascular risk factors | 1.2 (0.65–2.23) | |
I: 2922 patients; C: 7341 patients | (11) Exercise training completeda | 1.64 (0.57–4.71) | |
I: 4071 patients; C: 4898 patients | (12) Relaxation and stress management training completeda | 0.44 (0.14–1.41) | |
I: 4591 patients; C: 7341 patients | (13) Cardiovascular risk factors evaluated at discharge | 1.22 (0.4–3.76) | |
I: 4591 patients; C: 7341 patients | (14) Improvement in exercise capacity | 0.86 (0.69–1.07) | |
I: 4591 patients; C: 7341 patients | (15) Successful work resumption | 1.04 (0.86–1.24) | |
I: 4591 patients; C: 7341 patients | (16) Moderately active lifestyle norm met at discharge | 1.03 (0.82–1.29) | |
I: 4591 patients; C: 7341 patients | (17) Vigorously active lifestyle norm met at discharge | 0.88 (0.74–1.04) |